Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus TOBRAMYCIN AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus TOBRAMYCIN AND DEXAMETHASONE.
GENOPTIC vs TOBRAMYCIN AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Tobramycin: aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA. Dexamethasone: corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
1-2 drops of suspension into the conjunctival sac every 4-6 hours; in severe cases, every 2 hours initially, then taper.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Tobramycin: 2-3 hours in patients with normal renal function; prolonged (24-60 hours) in renal impairment. Dexamethasone: 3-5 hours in adults; prolonged in hepatic impairment.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Tobramycin is eliminated primarily by the kidneys via glomerular filtration, with 80-90% of an absorbed dose excreted unchanged in urine over 24 hours; minor biliary/fecal excretion (<1%). Dexamethasone is metabolized in the liver and excreted in urine (65%) and feces (35%) as metabolites.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic